Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find the link for the transcript of the Q4 FY24 Earnings Call conducted on April 25, 2024 and uploaded on the website of the Company on April 29, 2024. Syngene International Ltd - 539268 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation regarding submission of appeal to the National Faceless Appeal Centre against Order under Section 143(3) read with Section 144B of the Income Tax Act, 1961 Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication - Financial results.
Expect Syngene revenue to rise from high single digits to low double digits next year: Jonathan Hunt
Jonathan Hunt detailed the investment strategy of Syngene International, facing revenue growth challenges due to US biotech funding delays. Expecting high single to low double digits growth for FY25, with ongoing developments in various company facilities. Hunt says: "We deployed $55 million last year. Next year, we will be a little bit ahead of that." Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find the link for the audio recording of the Q4 FY24 Earnings Call conducted on April 25, 2024, and uploaded on the website of the Company on April 25, 2024.
Syngene International Results Earnings Call for Q4FY24
Conference Call with Syngene International Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Syngene's biologics division expands amid Q4 downturn, expects strong revenue growth ahead
Company cites moderated performance in Q3 and Q4 leading to a slower latter half Q4FY24 Quarterly & FY24 Annual Result Announced for Syngene International Ltd.
Pharmaceuticals company Syngene International announced Q4FY24 & FY24 results: Q4FY24 & FY24 Financial Highlights: Full-year revenue for FY24 increased by 9% to Rs 3,489 crore, with profit after tax (PAT) before exceptional items grew by 12% to Rs 519 crore compared to the previous fiscal year. Fourth quarter revenue saw a decline of 8% YoY to Rs 917 crore, but PAT increased by 6% to Rs 189 crore for the same period. EBITDA for FY24 was reported at Rs 1,105 crore, a 10% increase from the last year. EBITDA margin remained stable at 31% for the full financial year. The fourth quarter EBITDA margin improved by 298 basis points YoY to 34.6%. Full-year PAT after exceptional items for FY24 was up by 10% to Rs 510 crore over the previous year. PAT margin was consistent at 14% for both FY24 and FY23. Outlook and Projections: - Revenue growth for fiscal year 2025 is projected to be in the high single digits to low double digits, with a similar EBITDA margin as FY24 and single-digit PAT growth. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said, “While the fourth quarter performance came in lower than expected, the underlying driver - reduced demand for research and development services within US biotech stemming from a difficult funding environment - is well understood and already showing positive signs of recovery. Despite the business environment, we delivered growth during the year. This resilience is the result of our broad operating span and the investments made to establish our development and manufacturing divisions with biologics, in particular, delivering a strong performance throughout the year. I’m encouraged by the recent step up in new funding into US biotech and expect this to drive a recovery in demand for research and development services translating into revenue growth in the latter part of the year. Looking ahead, we expect revenue growth in fiscal year 2025 to be in the range of high single digits to low double digits with momentum building up during the year. We expect the EBITDA margin to be similar to the level delivered in fiscal year 2024 and PAT growth in single digits. The long-term indicators for the sector are positive and I am confident that we will continue to perform well in the long term.” Sibaji Biswas, Chief Financial Officer and Executive Director, Syngene International said, “We had a strong start to the year which moderated in the third and fourth quarters resulting in a slower second half of the fiscal year. We continued to manage costs proactively to deliver consistent operating leverage and maintain EBITDA margin around the expected level. Our net cashflow generated from operating activities for the year was strong at Rs 1,042 crore, which fully funded the capex and the acquisition of the biologics manufacturing plant. For fiscal year 2024, the Board of Directors has recommended a final dividend of Rs.1.25 per share, an increase of 150% over last year’s core dividend of 50 paise per share, subject to shareholders approval. As demand picks up in the year ahead, we will continue to strategically invest in areas that strengthen our position as a leading integrated provider of research, development and manufacturing services.” Result PDF Syngene International Ltd - 539268 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Intimation regarding submission of appeal to the Commissioner of Income-tax (Appeals).